The How And Why Behind A CNS Company Pivoting To Develop A Treatment For COVID-19
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs and company founders (view full video here). In this clip, Jonathan Javitt, M.D., CEO of NeuroRx, shares how his company, which had been focused on developing small molecule drugs primarily for CNS ailments, pivoted toward developing a treatment for respiratory failure of COVID-19 patients.
This website uses cookies to ensure you get the best experience on our website. Learn more